These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

584 related articles for article (PubMed ID: 32000630)

  • 41. Contemporary Review of Antithrombotic Therapy in Peripheral Artery Disease.
    Hess CN; Bonaca MP
    Circ Cardiovasc Interv; 2020 Oct; 13(10):e009584. PubMed ID: 33023325
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Vorapaxar: emerging evidence and clinical questions in a new era of PAR-1 inhibition.
    Ungar L; Rodriguez F; Mahaffey KW
    Coron Artery Dis; 2016 Nov; 27(7):604-15. PubMed ID: 27398626
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Vorapaxar in the treatment of cardiovascular diseases.
    Tantry US; Bliden KP; Chaudhary R; Novakovic M; Rout A; Gurbel PA
    Future Cardiol; 2020 Sep; 16(5):373-384. PubMed ID: 32308016
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Effect of age on efficacy and safety of vorapaxar in patients with non-ST-segment elevation acute coronary syndrome: Insights from the Thrombin Receptor Antagonist for Clinical Event Reduction in Acute Coronary Syndrome (TRACER) trial.
    Armaganijan LV; Alexander KP; Huang Z; Tricoci P; Held C; Van de Werf F; Armstrong PW; Aylward PE; White HD; Moliterno DJ; Wallentin L; Chen E; Harrington RA; Strony J; Mahaffey KW; Lopes RD
    Am Heart J; 2016 Aug; 178():176-84. PubMed ID: 27502866
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Tackling Elevated Risk in PAD: Focus on Antithrombotic and Lipid Therapy for PAD.
    Govsyeyev N; Nehler MR; Hiatt WR; Bonaca MP
    Curr Cardiol Rep; 2020 Jan; 22(3):13. PubMed ID: 31997026
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Comparison of rivaroxaban-based dual antithrombotic and antiplatelet therapies for symptomatic patients with lower-extremity peripheral artery disease post-revascularization: a retrospective cohort study.
    Ji Y; Wang B; Wu G; Zhang Y; Wang Q; Zhou M
    Ther Adv Chronic Dis; 2023; 14():20406223231213262. PubMed ID: 38085917
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Antithrombotic strategies for patients with coronary and lower extremity peripheral artery diseases: a narrative review.
    De Luca L; Bonaca MP; Magnani G
    Expert Rev Cardiovasc Ther; 2020 Dec; 18(12):881-889. PubMed ID: 33021875
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Rationale and design for the Vascular Outcomes study of ASA along with rivaroxaban in endovascular or surgical limb revascularization for peripheral artery disease (VOYAGER PAD).
    Capell WH; Bonaca MP; Nehler MR; Chen E; Kittelson JM; Anand SS; Berkowitz SD; Debus ES; Fanelli F; Haskell L; Patel MR; Bauersachs R; Hiatt WR
    Am Heart J; 2018 May; 199():83-91. PubMed ID: 29754671
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Adjunctive therapies to reduce thrombotic events in patients with a history of myocardial infarction: role of vorapaxar.
    Farag M; Patel H; Gorog DA
    Drug Des Devel Ther; 2015; 9():3801-9. PubMed ID: 26229441
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Rivaroxaban Plus Aspirin Versus Aspirin Alone After Endovascular Revascularization for Symptomatic PAD: Insights From VOYAGER PAD.
    Rymer J; Anand SS; Sebastian Debus E; Haskell LP; Hess CN; Jones WS; Muehlhofer E; Berkowitz SD; Bauersachs RM; Bonaca MP; Patel MR
    Circulation; 2023 Dec; 148(24):1919-1928. PubMed ID: 37850397
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Platelet Reactivity and Clinical Outcomes After Coronary Artery Implantation of Drug-Eluting Stents in Subjects With Peripheral Arterial Disease: Analysis From the ADAPT-DES Study (Assessment of Dual Antiplatelet Therapy With Drug-Eluting Stents).
    Gupta R; Kirtane AJ; Ozan MO; Witzenbichler B; Rinaldi MJ; Metzger DC; Weisz G; Stuckey TD; Brodie BR; Mehran R; Ben-Yehuda O; Stone GW
    Circ Cardiovasc Interv; 2017 Mar; 10(3):. PubMed ID: 28288963
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Dapagliflozin and Cardiac, Kidney, and Limb Outcomes in Patients With and Without Peripheral Artery Disease in DECLARE-TIMI 58.
    Bonaca MP; Wiviott SD; Zelniker TA; Mosenzon O; Bhatt DL; Leiter LA; McGuire DK; Goodrich EL; De Mendonca Furtado RH; Wilding JPH; Cahn A; Gause-Nilsson IAM; Johanson P; Fredriksson M; Johansson PA; Langkilde AM; Raz I; Sabatine MS
    Circulation; 2020 Aug; 142(8):734-747. PubMed ID: 32795086
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Vorapaxar in the secondary prevention of atherothrombosis.
    Tantry US; Liu F; Chen G; Gurbel PA
    Expert Rev Cardiovasc Ther; 2015 Dec; 13(12):1293-305. PubMed ID: 26559689
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Limb Outcomes With Ticagrelor Plus Aspirin in Patients With Diabetes Mellitus and Atherosclerosis.
    Bonaca MP; Bhatt DL; Simon T; Fox KM; Mehta S; Harrington RA; Leiter LA; Capell WH; Held C; Himmelmann A; Ridderstråle W; Chen J; Lee JJ; Song Y; Andersson M; Prats J; Kosiborod M; McGuire DK; Steg PG
    J Am Coll Cardiol; 2024 Apr; 83(17):1627-1636. PubMed ID: 38658101
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Association of Hypertension and Arterial Blood Pressure on Limb and Cardiovascular Outcomes in Symptomatic Peripheral Artery Disease: The EUCLID Trial.
    Fudim M; Hopley CW; Huang Z; Kavanagh S; Rockhold FW; Baumgartner I; Berger JS; Blomster JI; Fowkes FGR; Katona BG; Mahaffey KW; Norgren L; Ostrom C; Patel MR; Jones WS; Hiatt WR
    Circ Cardiovasc Qual Outcomes; 2020 Sep; 13(9):e006512. PubMed ID: 32862697
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Chronic kidney disease and risk for cardiovascular and limb outcomes in patients with symptomatic peripheral artery disease: The EUCLID trial.
    Hopley CW; Kavanagh S; Patel MR; Ostrom C; Baumgartner I; Berger JS; Blomster JI; Fowkes FGR; Jones WS; Katona BG; Mahaffey KW; Norgren L; Rockhold FW; Hiatt WR
    Vasc Med; 2019 Oct; 24(5):422-430. PubMed ID: 31339474
    [TBL] [Abstract][Full Text] [Related]  

  • 57. A review of antithrombotic therapy and the rationale and design of the randomized edoxaban in patients with peripheral artery disease (ePAD) trial adding edoxaban or clopidogrel to aspirin after femoropopliteal endovascular intervention.
    Tangelder MJ; Nwachuku CE; Jaff M; Baumgartner I; Duggal A; Adams G; Ansel G; Grosso M; Mercuri M; Shi M; Minar E; Moll FL
    J Endovasc Ther; 2015 Apr; 22(2):261-8. PubMed ID: 25809373
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Following the COMPASS: Antithrombotic Prescription Trends in Patients with Symptomatic Peripheral Arterial Disease following Revascularization.
    Elzawy G; Chan J; Eisenberg N; Roche-Nagle G
    Ann Vasc Surg; 2024 Sep; 106():341-349. PubMed ID: 38851315
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Rivaroxaban in Peripheral Artery Disease after Revascularization.
    Bonaca MP; Bauersachs RM; Anand SS; Debus ES; Nehler MR; Patel MR; Fanelli F; Capell WH; Diao L; Jaeger N; Hess CN; Pap AF; Kittelson JM; Gudz I; Mátyás L; Krievins DK; Diaz R; Brodmann M; Muehlhofer E; Haskell LP; Berkowitz SD; Hiatt WR
    N Engl J Med; 2020 May; 382(21):1994-2004. PubMed ID: 32222135
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Coronary stent thrombosis with vorapaxar versus placebo: results from the TRA 2° P-TIMI 50 trial.
    Bonaca MP; Scirica BM; Braunwald E; Wiviott SD; O'Donoghue ML; Murphy SA; Morrow DA
    J Am Coll Cardiol; 2014 Dec; 64(22):2309-17. PubMed ID: 25465416
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 30.